NO20072060L - 2-acylaminotiazolderivater - Google Patents

2-acylaminotiazolderivater

Info

Publication number
NO20072060L
NO20072060L NO20072060A NO20072060A NO20072060L NO 20072060 L NO20072060 L NO 20072060L NO 20072060 A NO20072060 A NO 20072060A NO 20072060 A NO20072060 A NO 20072060A NO 20072060 L NO20072060 L NO 20072060L
Authority
NO
Norway
Prior art keywords
acylaminotiazolderivater
compounds
receptor
implicated
neurological
Prior art date
Application number
NO20072060A
Other languages
English (en)
Inventor
Gitte Mikkelsen
Benny Bang-Andersen
Mogens Larsen
Anette Graven Sams
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20072060L publication Critical patent/NO20072060L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Oppfinnelsen vedrører forbindelser med formel I, hvori variablene er som definert i kravene, for anvendelse som et medikament. Forbindelsene er A2A-reseptorligander og er nyttige i behandlingen av nevrologiske og psykiatriske lidelser hvor en A2A-reseptor er implisert. ?? ?? ?? ?? 1
NO20072060A 2004-09-22 2007-04-23 2-acylaminotiazolderivater NO20072060L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61223604P 2004-09-22 2004-09-22
DKPA200401441 2004-09-22
PCT/DK2005/000591 WO2006032273A1 (en) 2004-09-22 2005-09-20 2-acylaminothiazole derivatives

Publications (1)

Publication Number Publication Date
NO20072060L true NO20072060L (no) 2007-04-23

Family

ID=35169521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072060A NO20072060L (no) 2004-09-22 2007-04-23 2-acylaminotiazolderivater

Country Status (8)

Country Link
US (1) US7910613B2 (no)
EP (1) EP1794157B1 (no)
AU (1) AU2005287729A1 (no)
CA (1) CA2581105A1 (no)
EA (1) EA200700707A1 (no)
MX (1) MX2007003381A (no)
NO (1) NO20072060L (no)
WO (1) WO2006032273A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
CA2617817C (en) 2005-08-02 2014-05-27 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing sleep disorders
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
JP5599311B2 (ja) * 2008-07-23 2014-10-01 協和発酵キリン株式会社 片頭痛治療剤
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE855120C (de) 1950-10-08 1953-01-05 Schering Ag Verfahren zur Herstellung von Aminosalicylsaeureamiden
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2903339B2 (ja) 1990-10-12 1999-06-07 大日精化工業株式会社 電子写真感光体
CA2219747C (en) 1995-05-18 2008-11-25 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivative, medicament containing the same, and intermediate for preparation of said compound
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
US6121301A (en) 1996-10-24 2000-09-19 Zeria Pharmaceutical Co., Ltd. Substituted benzoylaminothiazole derivatives and drugs containing the same
WO1999064418A1 (en) 1998-06-05 1999-12-16 Novartis Ag Aryl pyridinyl thiazoles
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AU2825000A (en) 1999-03-10 2000-09-28 Shionogi & Co., Ltd. Medicinal compositions with (2.2.1) and (3.1.1) bicycloskeleton antagonistic to both of pgd2/txa2 receptors
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
JPWO2001094309A1 (ja) 2000-06-02 2004-02-05 塩野義製薬株式会社 Ｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
MXPA03006510A (es) 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6624163B2 (en) 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
AU2003304527B2 (en) 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
JP4638355B2 (ja) 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
WO2006051704A1 (ja) 2004-11-15 2006-05-18 Taisho Pharmaceutical Co., Ltd. イミン化合物
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
CA2617817C (en) 2005-08-02 2014-05-27 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing sleep disorders
US20090005568A1 (en) 2005-08-18 2009-01-01 Pharmacopeia Drug Discovery, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases

Also Published As

Publication number Publication date
EA200700707A1 (ru) 2007-08-31
EP1794157A1 (en) 2007-06-13
CA2581105A1 (en) 2006-03-30
AU2005287729A1 (en) 2006-03-30
MX2007003381A (es) 2007-04-27
EP1794157B1 (en) 2014-02-26
WO2006032273A1 (en) 2006-03-30
US7910613B2 (en) 2011-03-22
US20090137642A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20070606L (no) Inhibitorer av IAP
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
MY135841A (en) Novel benzodioxoles
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
EG26020A (en) Derivatives 3- (Hetero Aryl-AXY) -2- Alkyl -1- AZA Dicyclic Alkyl Carbides Alpha 7- NACHR for the treatment of diseases of the central nervous system
TW200531689A (en) Therapeutic agents
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MXPA03012013A (es) Derivados de 1-oxa-2,8-diaza-spiro[4,5]dec-2-eno sustituidos como medicamento para el tratamiento de dolor.
DK2194053T3 (da) Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
TW200635903A (en) Therapeutic agents
TW200503710A (en) Novel compounds
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application